Doseology Sciences (XCNQ:MOOD) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Doseology Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Doseology Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Doseology Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Doseology Sciences's Cash-to-Debt or its related term are showing as below:

XCNQ:MOOD' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.51 Med: 3.9 Max: No Debt
Current: 26.45

During the past 4 years, Doseology Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 2.51. And the median was 3.90.

XCNQ:MOOD's Cash-to-Debt is ranked better than
65.91% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs XCNQ:MOOD: 26.45

Doseology Sciences Cash-to-Debt Historical Data

The historical data trend for Doseology Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Doseology Sciences Cash-to-Debt Chart

Doseology Sciences Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

No Debt

5.43

2.51

25.51

Doseology Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										3.06	2.88	25.51	29.38	No Debt

Competitive Comparison of Doseology Sciences's Cash-to-Debt

For the Biotechnology subindustry, Doseology Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Doseology Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's Cash-to-Debt falls into.

Doseology Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Doseology Sciences's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.301	/	(0.043	+	0.008)
	=	25.51

Doseology Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Doseology Sciences had no debt ⁽¹⁾.

Doseology Sciences (XCNQ:MOOD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Doseology Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Doseology Sciences (XCNQ:MOOD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (XCNQ:MOOD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

DOSEF:USA

Address

116 - 5100 Anderson Way, Unit 197, Vernon, BC, CAN, V1T 0C4

Website

https://www.doseology.com

Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

Doseology Sciences (XCNQ:MOOD) Headlines

No Headlines

Doseology Sciences (XCNQ:MOOD) Cash-to-Debt : No Debt (1) (As of Dec. 2023)